Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to NRG Oncology
Related studies linked through entity extraction aliases.
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
- Status
- TERMINATED
- Phase
- PHASE3
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
- Status
- TERMINATED
- Phase
- PHASE3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- Status
- RECRUITING
- Phase
- PHASE3
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
- Status
- WITHDRAWN
- Phase
- PHASE2/PHASE3
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2